Otsuka is voluntarily recalling certain lots of ABILIFY® (aripiprazole) Tablets due to cross-contamination from extremely small amounts of another active pharmaceutical ingredient previously manufactured on the same equipment. Based on sample testing performed, there is no material patient risk associated with the trace level of contamination found. The voluntary recall has been initiated by Otsuka out of an abundance of caution, with the knowledge of the U.S. Food and Drug Administration. This recall is limited to the United States.

Consumers who have a product that is being recalled and who have concerns, should consult with their healthcare provider or pharmacy. Adverse reactions or quality problems experienced with the use of this product should be reported.

Otsuka America Pharmaceutical, Inc. can be reached by phone at 1-833-468-7852 Monday – Friday, 9 a.m. – 5 p.m. Eastern Time or by email: or The FDA's MedWatch Adverse Event Reporting program can be reached either online or by phone. To complete and submit the report Online: or call 1-800-332-1088.

Read more here:

April 2024 01US24EBC0008

Comprehensive Support

We are dedicated to going above and beyond for healthcare professionals. That’s why we have created several communities that allow for the exchange of information and ideas on patient care to help healthcare professionals navigate the challenges they may face along a patient’s journey.


Education & Community



NephU is a growing community of nephrology healthcare professionals that was created to help improve the future outcomes for individuals with kidney disease and other related conditions through increased awareness, collaboration, and information-sharing.

Join NephU to participate in informational webinars, connect with others at educational events, access an on-demand library of educational materials and tools, including the ADPKD Simulator, and stay up-to-date on the latest news about healthcare topics and policy changes.



PsychU is a community for mental health professionals dedicated to improving care through information, discussion, and collaboration. It is composed of more than 75,000 physicians, psychiatrists, nurse practitioners, physician assistants, clinicians, care managers, nurses, pharmacists, medical directors, payers, administrators, and other mental healthcare professionals. 

Resources on PsychU are focused on such topics as schizophrenia, major depressive disorder, bipolar disorder, agitation, pseudobulbar affect, care coordination, digital health, psychiatric scales, as well as healthcare policy, quality, & payer administration. PsychU goes beyond the traditional educational resources, with PsychUsim and PsychUroleplay. PsychUsim, is an interactive disease state simulator showcasing the progression of different psychiatric illnesses while PsychUroleplay a virtual roleplay for practicing communication skills. The website also includes a patient and caregiver resource section that provides education on various mental health conditions. 


Global Council on Alzheimer’s Disease (GCAD)

Otsuka launched the GCAD collaboration group with a focus on patient-centered care. The community includes leaders and influencers from advocacy groups, healthcare professionals, academics, and leaders from financial institutions. Participants share knowledge and ideas at educational summits as part of an ongoing effort to determine the best ways to work together to meet patients’ needs.